Ephedrine / ECA Stack
ECA
Ephedrine is a plant-derived (Ephedra/ma huang) sympathomimetic amine; the "ECA stack" combines Ephedrine, Caffeine, and Aspirin, popularized for fat loss and stimulant/thermogenic effect. In human RCTs and a JAMA meta-analysis it produces only modest short-term weight loss (~0.9 kg/month more than placebo, no data beyond 6 months) while measurably raising heart rate, blood pressure, and the odds of psychiatric, autonomic, GI, and palpitation symptoms. The main risks are cardiovascular and cerebrovascular: FDA adverse-event case series link ephedra-alkaloid supplements to hypertension, tachycardia/palpitations, arrhythmia, seizures, ischemic and hemorrhagic stroke, myocardial events, permanent disability, and death. Because it is a stimulant with a narrow benefit-to-risk margin, the aspirin component adds bleeding risk, and product ephedrine content is often mislabeled, this is a high-risk compound; ephedra-containing supplements were removed from the US market. This monograph is risk-forward and not a recommendation to use.
Mechanism of action
Pharmacokinetics
Ephedrine elimination half-life approximately 3-6 hours after oral dosing; markedly prolonged when urine is alkaline (because reabsorption increases) and shortened in acidic urine, so half-life is pH-dependent and variable between individuals.
Sympathomimetic/stimulant effects last roughly 4-6 hours per oral dose; single-dose studies show systolic blood pressure peaking ~1.5 hours post-dose and heart rate rising over several hours (max change ~6 hours). Caffeine co-ingestion (half-life ~5-6 h, longer with oral contraceptives) extends the stimulant window.
Oral (tablets/capsules in supplement/ECA use).
Ephedrine undergoes minimal hepatic metabolism and is largely eliminated unchanged by the kidney; renal clearance is strongly urine-pH dependent (alkaline urine reduces clearance and can substantially prolong half-life). Caffeine is cleared hepatically via CYP1A2. This section is for monitoring/washout context only, not for evading testing.
For monitoring and washout planning, not drug-test evasion.
Physiological & performance effects
- Modest short-term weight and body-fat loss versus placebo in overweight adults (~0.9 kg/month more than placebo; RCTs up to 6 months); no long-term (>6 month) efficacy data
- Thermogenesis and increased resting energy expenditure via sympathoadrenal/beta-adrenergic activation
- Appetite suppression contributing to weight loss
- Ephedrine-caffeine combination preserves fat-free (lean) mass during energy restriction relative to placebo
- Increased heart rate and, acutely, increased systolic blood pressure (partial tolerance to the pressor effect develops)
- Stimulant/CNS-arousal effects including insomnia and jitteriness
- No adequate evidence supporting improved athletic performance (trials heterogeneous/insufficient)
Adverse effects by system
Most important adverse system. RCTs show increased heart rate and acute systolic blood pressure rises; meta-analysis found 2-4x increased odds of palpitations and autonomic symptoms. FDA case-series review linked ephedra alkaloids to hypertension (most frequent event), palpitations/tachycardia, arrhythmia, myocardial events, and cardiac death. Serious events are individually rare but can be catastrophic.
Ephedrine itself is not an established hepatotoxin and controlled trials did not report liver injury. Isolated case series of acute hepatitis/hepatic failure are reported with multi-ingredient ephedra-containing supplements (e.g., Herbalife products), but causal attribution to ephedrine specifically is uncertain given confounding ingredients. Overall liver risk from ephedrine per se appears low with no adequate human data establishing direct hepatotoxicity.
No known direct effect on the hypothalamic-pituitary-testicular/gonadal axis; ephedrine is a sympathomimetic, not a hormonal agent, and there are no human data showing testosterone suppression. It can transiently affect metabolic/thermogenic and glycemic parameters via adrenergic activity.
No adequate human data on fertility or reproductive outcomes in adults using ECA. Not studied for this use; use in pregnancy is not addressed here beyond contraindication.
Meta-analysis found 2-4x increased odds of psychiatric symptoms; reported effects include insomnia, anxiety, irritability, agitation, and (in case reports) psychosis and seizures. CNS symptoms accounted for a substantial share of serious FDA-reported events.
No established direct nephrotoxicity in trials. Relevant renal pharmacology is that elimination is renal and urine-pH dependent; sympathomimetic hypertensive surges could theoretically stress the vasculature. No adequate human data on direct kidney injury.
Ephedrine has no established hematologic toxicity. The aspirin component of the ECA stack impairs platelet function and increases bleeding risk (GI bleeding, bruising), which is the main hematologic concern of the stack rather than of ephedrine itself.
No characteristic or well-documented dermatologic toxicity; sweating/diaphoresis can occur from adrenergic stimulation. No adequate human data indicating specific skin injury.
HPTA suppression & recovery
Suppression: None known / not applicable
Ephedrine is a sympathomimetic stimulant, not an androgen, SERM, or hormonal agent, and there are no human data indicating it suppresses the HPTA/HPG axis, so no post-cycle or SERM-based recovery framework applies. If HPTA or hormonal concerns arise (e.g., from concurrent agents), evaluation and management should be directed by an endocrinologist. Any SERM use, if separately indicated, should be single-agent and physician-directed; dual-SERM protocols are never appropriate.
Monitoring
Cadence: Establish baseline before any use; recheck blood pressure and heart rate within the first days and regularly thereafter; clinician review at least periodically. Because human safety data beyond 6 months do not exist, do not treat prolonged use as validated.
- Chest pain, pressure, or palpitations
- Severe or persistent headache, very high blood pressure readings
- Sudden weakness, numbness, facial droop, trouble speaking or vision (stroke warning)
- Fainting, seizure, or irregular/racing heartbeat
- Severe anxiety, agitation, confusion, or psychosis
- Shortness of breath
- Black/tarry stools, vomiting blood, or unusual bruising/bleeding (aspirin component)
Contraindications
- Coronary artery disease, prior myocardial infarction, or other structural/ischemic heart disease
- Hypertension (especially uncontrolled) and arrhythmias
- History of stroke, TIA, or cerebrovascular disease
- Concurrent use of MAO inhibitors or other sympathomimetic/stimulant drugs (hypertensive crisis risk)
- Seizure disorder
- Hyperthyroidism
- Pheochromocytoma
- Anxiety disorders or psychosis
- Pregnancy and breastfeeding
- Narrow-angle glaucoma, urinary retention/BPH
- Aspirin component: peptic ulcer disease, bleeding disorders, anticoagulant use, aspirin/NSAID allergy, or asthma with aspirin sensitivity
Interaction profile
- MajorWith an anabolic steroid: Additive cardiovascular strain
- MajorWith a stimulant: Additive cardiovascular strain
- ModerateWith a SARM: Additive cardiovascular strain
- MajorWith thyroid hormone: Additive cardiovascular strain
- ModerateWith a GLP-1 / incretin agonist: Additive cardiovascular strain
- ModerateWith a melanocortin agonist: Additive hypertension
- MajorWith a QT-prolonging drug: QT prolongation
- ContraindicatedWith DNP: Additive cardiovascular strain
Check a specific combination in the interaction checker.
Reducing harm & when to stop
- Discuss with a physician before any use and obtain baseline blood pressure, heart rate, and an ECG if you have any cardiac risk factors; do not use if you have heart disease, high blood pressure, arrhythmia, prior stroke, seizures, hyperthyroidism, or anxiety/psychiatric disorders.
- Serious cardiovascular and neurological events (stroke, arrhythmia, seizure, sudden death) are the main dangers and can occur even in young healthy people; this is not a validated or low-risk fat-loss tool.
- Stop immediately and seek emergency care for chest pain, palpitations, severe headache, very high blood pressure, fainting, seizure, or any stroke warning sign (weakness, numbness, facial droop, speech or vision changes).
- Do not combine with other stimulants (additional caffeine, decongestants, other sympathomimetics) or with MAO inhibitors; avoid before or during intense exertion or in hot environments where cardiovascular strain and heat stress compound.
- The aspirin component adds GI bleeding and general bleeding risk; avoid if you have ulcers, bleeding disorders, aspirin/NSAID allergy, aspirin-sensitive asthma, or take anticoagulants.
- Supplement ephedrine content is frequently mislabeled and inconsistent, so actual exposure and risk are unpredictable.
- No human data exist beyond ~6 months; there is no established safe long-term regimen.
- Contraindicated in pregnancy and breastfeeding.
Citations (13)
Every clinical claim above is tied to a primary source. Overall evidence grade B — graded to the best available evidence for its core claims.
- 01
Ephedrine/ephedra with caffeine produce modest short-term weight loss (~0.9 kg/month more than placebo) with no long-term data, and are associated with 2.2-3.6x increased odds of psychiatric, autonomic, or GI symptoms and palpitations; no adequate evidence for athletic performance.
Meta-analysisDOI 10.1001/jama.289.12.1537 ↗
- 02
In a 6-month RCT, herbal ephedra/caffeine (90/192 mg/day) reduced body weight and fat and increased heart rate (+4 vs -3 bpm) with small BP changes and increased insomnia, dry mouth, and heartburn.
- 03
In an 8-week RCT, ma huang/guarana (72 mg/day ephedrine alkaloids, 240 mg/day caffeine) produced greater weight and fat loss than placebo; 23% of treated subjects withdrew due to potential treatment-related effects (dry mouth, insomnia, headache most common).
- 04
In a 12-week RCT, an ephedrine/caffeine herbal product produced ~1.5 kg greater weight loss than placebo without significant increases in blood pressure, pulse, or adverse-event rate; product assayed at ~half of labeled ephedrine/caffeine content, illustrating supplement mislabeling.
- 05
Over a 14-day RCT, an ephedra-caffeine weight-loss supplement produced no significant changes in heart rate, blood pressure, ejection fraction, or valve function in healthy overweight adults.
- 06
FDA adverse-event review linked ephedra-alkaloid supplements to serious cardiovascular and CNS events: hypertension (most frequent), palpitations/tachycardia, stroke, and seizures, with 10 deaths and 13 permanent disabilities among reviewed cases.
Case seriesDOI 10.1056/NEJM200012213432502 ↗
- 07
Ischemic (and risk of hemorrhagic) stroke reported in patients using over-the-counter ephedra-containing products.
Case seriesDOI 10.1016/j.jns.2003.08.012 ↗
- 08
PK/PD modeling of oral ephedrine (one-compartment, first-order absorption/elimination) shows rapid systolic BP rise that is largely offset by compensatory tolerance (tolerance half-life ~15 min); heart-rate effect is linear.
- 09
Oral ephedrine pharmacokinetics and half-life characterized in humans; tolerance to therapeutic doses is pharmacodynamic rather than disposition-related.
- 10
Single-dose ephedra/caffeine supplement PK/PD: clearance and half-lives comparable to pharmaceutical formulations, elimination prolonged with high urine pH; systolic BP rose ~14 mmHg (peak ~90 min) and heart rate ~15 bpm (peak ~6 h).
- 11
Ephedrine/caffeine exert thermogenic effects through activation of the sympathoadrenal system and peripheral beta-adrenoceptors.
- 12
Ephedrine-caffeine combination is superior to placebo and to either agent alone for weight reduction, preserves fat-free mass, and enhances fat loss (~75% via anorexia, ~25% via thermogenesis).
- 13
Acute hepatitis and hepatic failure reported in a case series of multi-ingredient ephedra-containing (Herbalife) supplement users, with recurrence on rechallenge; causality specific to ephedrine not established.
Case seriesDOI 10.1016/j.jhep.2007.06.016 ↗
Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice